Production (Stage)
Turnstone Biologics Corp.
TSBX
$0.3329
-$0.0065-1.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -91.54% | -22.12% | 1.78% | 27.02% | -95.68% |
| Gross Profit | 91.54% | 22.12% | -1.78% | -27.02% | -115.28% |
| SG&A Expenses | -1.92% | -26.83% | -17.11% | -7.13% | 21.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -55.71% | -23.42% | -2.97% | 0.94% | 8.41% |
| Operating Income | 55.71% | 23.42% | 2.97% | -0.94% | -9,462.44% |
| Income Before Tax | 39.82% | 27.55% | -2.86% | 0.94% | -139,992.86% |
| Income Tax Expenses | -87.50% | 606.06% | -2,372.73% | 133.33% | 119.51% |
| Earnings from Continuing Operations | 39.85% | 21.75% | 1.66% | 0.91% | -28,966.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.85% | 21.75% | 1.66% | 0.91% | -28,966.18% |
| EBIT | 55.71% | 23.42% | 2.97% | -0.94% | -9,462.44% |
| EBITDA | 56.08% | 22.32% | 1.94% | -2.07% | -2,270.11% |
| EPS Basic | 40.19% | 22.18% | 25.74% | 87.76% | 83.38% |
| Normalized Basic EPS | 40.15% | 12.98% | 22.33% | 87.76% | -495.18% |
| EPS Diluted | 40.19% | 22.18% | 25.74% | 87.76% | 83.38% |
| Normalized Diluted EPS | 40.15% | 12.98% | 22.33% | 87.76% | -495.18% |
| Average Basic Shares Outstanding | 0.55% | 0.55% | 32.42% | 708.99% | 725.98% |
| Average Diluted Shares Outstanding | 0.55% | 0.55% | 32.42% | 708.99% | 725.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |